BioSpace News Archive

Ra Medical Systems, Inc. announces that its audited consolidated financial statements for the fiscal year ended December 31, 2021 included in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2022 and Amended Form 10-K/A filed with the SEC on July 7, 2022 contained an audit report from its independent registered public accounting firm which included a going concern emphasis of matter paragraph.

Reata Pharmaceuticals, Inc. announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company’s business operations and clinical development programs on August 8, 2022, before the U.S. financial markets open.

Immunocore Holdings plc today announced that initial data from its Phase 1 study of IMC-F106C, the first PRAME x CD3 ImmTAC bispecific in multiple solid tumors has been accepted for an oral presentation during a proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.

Taysha Gene Therapies, Inc. today announced its participation in panel discussions at the BTIG Biotechnology Conference on August 8th and the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10th.

ALX Oncology Holdings Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to evorpacept, a next generation CD47 blocker, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma (“HNSCC”).

HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its unaudited financial results and provides updates on key clinical and commercial developments for the six months ended June 30, 2022.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata,

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Torii Pharmaceutical Co., Ltd. (“Torii”) dosed the first patient in its Phase 3 trial of VP-102.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a.m. EDT to discuss the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream 0.3% for treatment of plaque psoriasis.